Peroxisome Proliferator-Activated Receptors α and γ are Linked with Alcohol Consumption in Mice and Withdrawal and Dependence in Humans

Alcoholism: Clinical and Experimental Research

Volumn 39, Issue 1, 2015, Pages 136-145

  Blednov, Yuri A ^a   Benavidez, Jillian M ^a   Black, Mendy ^a   Ferguson, Laura B ^a   Schoenhard, Grant L ^b   Goate, Alison M ^c   Edenberg, Howard J ^d   Wetherill, Leah ^d   Hesselbrock, Victor ^e   Foroud, Tatiana ^d   Adron Harris, R ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Pain Therapeutics Inc   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

C57BL 6J; Fenofibrate; Fenofibric Acid; Genome Wide Association Study; Pioglitazone; Tesag litazar; Two Bottle Choice

Indexed keywords

ALCOHOL; BEZAFIBRATE; FENOFIBRATE; FENOFIBRIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TESAGLITAZAR; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALKANESULFONIC ACID; PHENYLPROPIONIC ACID DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINGE DRINKING; BRAIN LEVEL; BRAIN TISSUE; CONTROLLED STUDY; FLUID INTAKE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN GENOME; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; AGONISTS; ANIMAL; BLOOD; BRAIN; DRINKING BEHAVIOR; FEMALE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; METABOLISM;

MUS; RATTUS;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; ALKANESULFONATES; ANIMALS; BEZAFIBRATE; BRAIN; FEMALE; FENOFIBRATE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIVER; MALE; MICE; PHENYLPROPIONATES; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR ALPHA; PPAR GAMMA; THIAZOLES; THIAZOLIDINEDIONES;

EID: 84921554812     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/acer.12610     Document Type: Article

References (57)

1. Austin S, St-Pierre J (2012) PGC1alpha and mitochondrial metabolism-emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci 125:4963-4971.
2. Barson JR, Karatayev O, Chang GQ, Johnson DF, Bocarsly ME, Hoebel BG, Leibowitz SF (2009) Positive relationship between dietary fat, ethanol intake, triglycerides, and hypothalamic peptides: counteraction by lipid-lowering drugs. Alcohol 43:433-441.
3. Begleiter H, Reich T, Hesselbrock V, Porjesz B, Li TK, Schuckit M, Edenberg H, Rice JP (1995) The collaborative study on the genetics of alcoholism. Alcohol Health Res World 19:228-236.
4. Bhateja DK, Dhull DK, Gill A, Sidhu A, Sharma S, Reddy BV, Padi SS (2012) Peroxisome proliferator-activated receptor-alpha activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms. Eur J Pharmacol 674:33-43.
5. Blednov YA, Harris RA (2008) Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions. Int J Neuropsychopharmacol 11:775-793.
6. Boersma MC, Meffert MK (2008) Novel roles for the NF-kappaB signaling pathway in regulating neuronal function. Sci Signal 1: pe7.
7. Bordet R, Gele P, Duriez P, Fruchart JC (2006) PPARs: a new target for neuroprotection. J Neurol Neurosurg Psychiatry 77:285-287.
8. Browning BL, Browning SR (2009) A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet 84:210-223.
9. Bucholz KK, Cadoret R, Cloninger CR, Dinwiddie SH, Hesselbrock VM, Nurnberger JI Jr, Reich T, Schmidt I, Schuckit MA (1994) A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA. J Stud Alcohol 55:149-158.
10. Campolongo P, Roozendaal B, Trezza V, Cuomo V, Astarita G, Fu J, McGaugh JL, Piomelli D (2009) Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc Natl Acad Sci U S A 106:8027-8031.
11. Cheatham WW (2010) Peroxisome proliferator-activated receptor translational research and clinical experience. Am J Clin Nutr 91:262S-266S.
12. Chen MH, Yang Q (2010) GWAF: an R package for genome-wide association analyses with family data. Bioinformatics 26:580-581.
13. Chen WM, Manichaikul A, Rich SS (2009) A generalized family-based association test for dichotomous traits. Am J Hum Genet 85:364-376.
14. Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, Karlsson U, Lindstedt EL, Bamberg K (2001) Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9:699-706.
15. Dasgupta S, Roy A, Jana M, Hartley DM, Pahan K (2007) Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol Pharmacol 72:934-946.
16. Daynes RA, Jones DC (2002) Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2:748-759.
17. Edenberg HJ, Xuei X, Wetherill LF, Bierut L, Bucholz K, Dick DM, Hesselbrock V, Kuperman S, Porjesz B, Schuckit MA, Tischfield JA, Almasy LA, Nurnberger JI Jr, Foroud T (2008) Association of NFKB1, which encodes a subunit of the transcription factor NF-kappaB, with alcohol dependence. Hum Mol Genet 17:963-970.
18. Enomoto N, Takei Y, Hirose M, Konno A, Shibuya T, Matsuyama S, Suzuki S, Kitamura KI, Sato N (2003) Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J Pharmacol Exp Ther 306:846-854.
19. Ferguson LB, Most D, Blednov YA, Harris RA (2014) PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption. Neuropharmacology 86:397-407.
20. Foroud T, Edenberg HJ, Goate A, Rice J, Flury L, Koller DL, Bierut LJ, Conneally PM, Nurnberger JI, Bucholz KK, Li TK, Hesselbrock V, Crowe R, Schuckit M, Porjesz B, Begleiter H, Reich T (2000) Alcoholism susceptibility loci: confirmation studies in a replicate sample and further mapping. Alcohol Clin Exp Res 24:933-945.
21. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425: 90-93.
22. Gamble C, McIntosh K, Scott R, Ho KH, Plevin R, Paul A (2012) Inhibitory kappa B kinases as targets for pharmacological regulation. Br J Pharmacol 165:802-819.
23. Gupta SC, Sundaram C, Reuter S, Aggarwal BB (2010) Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 1799:775-787.
24. Harris RA, Blednov YA (2013) Neuroimmune genes and alcohol drinking behavior, in Neural-Immune Interactions in Brain Function and Alcohol Related Disorders (Cui C, Grandison L, Noronha A eds), pp 425-440. Springer, New York, NY.
25. Hesselbrock M, Easton C, Bucholz KK, Schuckit M, Hesselbrock V (1999) A validity study of the SSAGA - a comparison with the SCAN. Addiction 94:1361-1370.
26. Huang MC, Schwandt ML, Chester JA, Kirchhoff AM, Kao CF, Liang T, Tapocik JD, Ramchandani VA, George DT, Hodgkinson CA, Goldman D, Heilig M (2014) FKBP5 moderates alcohol withdrawal severity: human genetic association and functional validation in knockout mice. Neuropsychopharmacology 39: 2029-2038.
27. Jiang Z, Rompala GR, Zhang S, Cowell RM, Nakazawa K (2013) Social isolation exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons. Biol Psychiatry 73:1024-1034.
28. Kang SJ, Rangaswamy M, Manz N, Wang JC, Wetherill L, Hinrichs T, Almasy L, Brooks A, Chorlian DB, Dick D, Hesselbrock V, Kramer J, Kuperman S, Nurnberger J Jr, Rice J, Schuckit M, Tischfield J, Bierut LJ, Edenberg HJ, Goate A, Foroud T, Porjesz B (2012) Family-based genome-wide association study of frontal theta oscillations identifies potassium channel gene KCNJ6. Genes Brain Behav 11:712-719.
29. Kao CH, Hsiang CY, Ho TY (2012) Assessment of chitosan-affected metabolic response by peroxisome proliferator-activated receptor bioluminescent imaging-guided transcriptomic analysis. PLoS ONE 7:e34969.
30. Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3:17-26.
31. Kreisler A, Duhamel A, Vanbesien-Mailliot C, Destee A, Bordet R (2010) Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease. Behav Pharmacol 21:194-205.
32. Le Foll B, Di Ciano P, Panlilio LV, Goldberg SR, Ciccocioppo R (2013) Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence. Curr Drug Targets 14:768-776.
33. Ljung B, Bamberg K, Dahllof B, Kjellstedt A, Oakes ND, Ostling J, Svensson L, Camejo G (2002) AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 43:1855-1863.
34. Mandrekar-Colucci S, Sauerbeck A, Popovich PG, McTigue DM (2013) PPAR agonists as therapeutics for CNS trauma and neurological diseases. ASN Neuro 5:e00129.
35. Marche K, Danel T, Bordet R (2011) Fetal alcohol-induced hyperactivity is reversed by treatment with the PPARalpha agonist fenofibrate in a rat model. Psychopharmacology 214:285-296.
36. Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, Scherma M, Fratta W, Fadda P, Barnes C, Redhi GH, Yasar S, Le Foll B, Tanda G, Piomelli D, Goldberg SR (2011) Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 69:633-641.
37. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A (2014) Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 174:70-77.
38. Mayfield J, Ferguson L, Harris RA (2013) Neuroimmune signaling: a key component of alcohol abuse. Curr Opin Neurobiol 23:513-520.
39. Nakajima T, Tanaka N, Kanbe H, Hara A, Kamijo Y, Zhang X, Gonzalez FJ, Aoyama T (2009) Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism. Mol Pharmacol 75:782-792.
40. Okvist A, Johansson S, Kuzmin A, Bazov I, Merino-Martinez R, Ponomarev I, Mayfield RD, Harris RA, Sheedy D, Garrick T, Harper C, Hurd YL, Terenius L, Ekstrom TJ, Bakalkin G, Yakovleva T (2007) Neuroadaptations in human chronic alcoholics: dysregulation of the NF-kappaB system. PLoS ONE 2:e930.
41. Osterndorff-Kahanek E, Ponomarev I, Blednov YA, Harris RA (2013) Gene expression in brain and liver produced by three different regimens of alcohol consumption in mice: comparison with immune activation. PLoS ONE 8:e59870.
42. Panlilio LV, Justinova Z, Mascia P, Pistis M, Luchicchi A, Lecca S, Barnes C, Redhi GH, Adair J, Heishman SJ, Yasar S, Aliczki M, Haller J, Goldberg SR (2012) Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings. Neuropsychopharmacology 37:1838-1847.
43. Ponomarev I, Wang S, Zhang L, Harris RA, Mayfield RD (2012) Gene coexpression networks in human brain identify epigenetic modifications in alcohol dependence. J Neurosci 32:1884-1897.
44. Rhodes JS, Best K, Belknap JK, Finn DA, Crabbe JC (2005) Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. Physiol Behav 84:53-63.
45. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278:704-711.
46. Schmid JA, Birbach A (2008) IkappaB kinase beta (IKKbeta/IKK2/IKBKB) - a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev 19:157-165.
47. Schnegg CI, Robbins ME (2011) Neuroprotective mechanisms of PPARdelta: modulation of oxidative stress and inflammatory processes. PPAR Res 2011:373560.
48. Stopponi S, de Guglielmo G, Somaini L, Cippitelli A, Cannella N, Kallupi M, Ubaldi M, Heilig M, Demopulos G, Gaitanaris G, Ciccocioppo R (2013) Activation of PPARgamma by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats. Alcohol Clin Exp Res 37:1351-1360.
49. Stopponi S, Somaini L, Cippitelli A, Cannella N, Braconi S, Kallupi M, Ruggeri B, Heilig M, Demopulos G, Gaitanaris G, Massi M, Ciccocioppo R (2011) Activation of nuclear PPARgamma receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiatry 69:642-649.
50. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR Jr, Sternbach DD (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity. Bioorg Med Chem Lett 13:1517-1521.
51. Tellez LA, Medina S, Han W, Ferreira JG, Licona-Limón P, Ren X, Lam TT, Schwartz GJ, de Araujo IE (2013) A gut lipid messenger links excess dietary fat to dopamine deficiency. Science 341:800-802.
52. Truitt JM, Blednov YA, Benavidez J, Black M, Ponomareva O, Law J, Lasek AW, Mayfield RD, Harris RA (2013) Inhibition of IKKbeta reduces ethanol consumption in C57Bl/6 mice. 36th Annual Meeting of the Research Society on Alcoholism, June 22-26, Orlando, Florida. Alcohol Clin Exp Res 37(Suppl. 2): 246A.
53. Wallenius K, Kjellstedt A, Thalén P, Löfgren L, Oakes ND (2013) The PPAR α/γ agonist, tesaglitazar, improves insulin mediated switching of tissue glucose and free fatty acid utilization in vivo in the obese zucker rat. PPAR Res 2013:305347.
54. Wang G, Namura S (2011) Effects of chronic systemic treatment with peroxisome proliferator-activated receptor α activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice. Neurosci Res 70:230-237.
55. Wang JC, Foroud T, Hinrichs AL, Le NX, Bertelsen S, Budde JP, Harari O, Koller DL, Wetherill L, Agrawal A, Almasy L, Brooks AI, Bucholz K, Dick D, Hesselbrock V, Johnson EO, Kang S, Kapoor M, Kramer J, Kuperman S, Madden PA, Manz N, Martin NG, McClintick JN, Montgomery GW, Nurnberger JI Jr, Rangaswamy M, Rice J, Schuckit M, Tischfield JA, Whitfield JB, Xuei X, Porjesz B, Heath AC, Edenberg HJ, Bierut LJ, Goate AM (2013) A genome-wide association study of alcohol-dependence symptom counts in extended pedigrees identifies C15orf53. Mol Psychiatry 18:1218-1224.
56. Weil A, Caldwell J, Strolin-Benedetti M (1988) The metabolism and disposition of fenofibrate in rat, guinea pig, and dog. Drug Metab Dispos 16:302-309.
57. Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527-550.